Pharmaceutical

STAT+: Oncologists more likely to provide low-value car...

Oncologists were more likely to provide low-value cancer care after receiving mo...

STAT+: Under-the-skin injection of Eisai’s Leqembi is a...

A version of the Alzheimer’s disease drug Leqembi that can be given with a simpl...

Abemaciclib by Eli Lilly and Co for Neuroblastoma: Like...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in P...

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai)...

Alimta by Eli Lilly and Co for Triple-Negative Breast C...

Alimta is under clinical development by Eli Lilly and Co and currently in Phase ...

Trametinib dimethyl sulfoxide by Novartis for Relapsed ...

Trametinib dimethyl sulfoxide is under clinical development by Novartis and curr...

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai)...

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai)...

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai)...

Surufatinib by Hutchison MediPharma for Neuroendocrine ...

Surufatinib is under clinical development by Hutchison MediPharma and currently ...

Ataluren by PTC Therapeutics for Duchenne Muscular Dyst...

Ataluren is under clinical development by PTC Therapeutics and currently in Phas...

SOF-10 by Chugai Pharmaceutical for Gastric Cancer: Lik...

SOF-10 is under clinical development by Chugai Pharmaceutical and currently in P...

STAT+: Pharmalittle: Pharma moves closer to a pricing d...

The pharmaceutical industry is close to a deal with the U.K. government over dru...

STAT+: Startup launches with $245 million for twice yea...

A new biotech has raised $245 million to test a new asthma medication that could...

STAT+: ‘Missed opportunities’: Why a U.K. government pl...

The U.K. plans to create what resembles the OpenPayments database in the U.S., w...

STAT+: For Parkinson’s disease, advances spurred by App...

After nearly a decade of development, Apple Watch is now being leveraged on an e...